Nkarta, Inc.
NKTXHealthcare|Biotechnology|US
$1.73
+0.16 (+10.19%)
Tangible Book / Share
$2.89
Cash / Share
$2.10
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06733935 A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Systemic Sclerosis, Idiopathic Inflammatory Myopathies | P1P2 | Recruiting | 240 | Open-label | NKX019, Fludarabine, Cyclophosphamide |
| NCT06557265 A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Lupus Nephritis, Primary Membranous Nephropathy | P1P2 | Recruiting | 120 | Open-label | NKX019, Fludarabine, Cyclophosphamide |
| NCT04623944 NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | Relapsed/Refractory AML, AML, Adult | P1 | Active | 61 | Open-label | NKX101 - CAR NK cell therapy |
| NCT05020678 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | P1 | Active | 150 | Open-label | NKX019 |
| NCT06518668 A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P1 | By Invite | 6 | Open-label | NKX019, Cyclophosphamide LD |